TGF-β-based immunotherapy for cancer: Breaching the tumor firewall

Ali H. Shah, Chung Lee*

*Corresponding author for this work

Research output: Contribution to journalReview article

26 Scopus citations

Abstract

Many malignant cells secrete transforming growth factor-β (TGF-β), a potent immunosuppresant, suggesting that TGF-β production may represent a significant tumor escape mechanism from host immunosurveillance. Establishment of a leukocyte subpopulation with disrupted TGF-β signaling in the tumor-bearing host offers a potential means for immunotherapy of cancer. Downregulation of TGF-β secretion in tumor cells results in restoration of immunogenicity in the host, while T-cell insensitivity to TGF-β results in accelerated differentiation and autoimmunity, elements of which may be required in order to combat self-antigen-expressing tumors in a tolerized host. The rationale, approaches, and potential pitfalls of this strategy will be discussed. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)167-172
Number of pages6
JournalProstate
Volume45
Issue number2
DOIs
StatePublished - Oct 16 2000

Keywords

  • Immunotherapy
  • Transforming growth factor-β
  • Tumor immunosurveillance

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'TGF-β-based immunotherapy for cancer: Breaching the tumor firewall'. Together they form a unique fingerprint.

  • Cite this